pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Bafiertam
drug
save

monomethyl fumarate DR

Marketedupdated 3mo ago
by Cycle Pharmaceuticals Ltd
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying monomethyl fumarate DR

  • —Observational Study of Persistence on Bafiertam Treatment in Routine Clinical Practiceterminatedn=25

Patent cliff

source: FDA Orange Book
first barrier falls
Feb 27, 2035
~8.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (21)

  • Feb 27, 2035formulationUS 10098863
  • Feb 27, 2035formulationUS 10105335
  • Feb 27, 2035formulationUS 10105336
  • Feb 27, 2035formulationUS 10105337
  • Feb 27, 2035formulationUS 10918615
  • Feb 27, 2035method-of-use (U-1384)US 10918616
  • Feb 27, 2035formulationUS 10918617
  • Feb 27, 2035formulationUS 10945985
  • Feb 27, 2035method-of-use (U-1384)US 11590095
  • Feb 27, 2035method-of-use (U-1384)US 11903918
  • Feb 27, 2035formulationUS 9326947
  • Feb 27, 2035method-of-use (U-1384)US 9326965
  • Feb 27, 2035method-of-use (U-1384)US 9511043
  • Feb 27, 2035formulationUS 9517209
  • Feb 27, 2035formulationUS 9566259
  • Feb 27, 2035method-of-use (U-1384)US 9636318
  • Feb 27, 2035formulationUS 9636319
  • Feb 27, 2035method-of-use (U-1384)US 9814691
  • Feb 27, 2035method-of-use (U-1384)US 9814692
  • Feb 27, 2035formulationUS 9820960
  • Feb 27, 2035formulationUS 9820961

News(0)

no news has mentioned this drug yet

brand
Bafiertam
generic
monomethyl fumarate
indication
Relapsing Remitting Multiple Sclerosis (RRMS)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 22m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?